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Summary
Smith-Lemli-Opitz syndrome (SLOS), an autosomal re-
cessive malformation syndrome, ranges in clinical se-
verity from mild dysmorphism and moderate mental re-
tardation to severe congenital malformation and in-
trauterine lethality. Mutations in the gene for D7-sterol
reductase (DHCR7), which catalyzes the final step in
cholesterol biosynthesis in the endoplasmic reticulum
(ER), cause SLOS. We have determined, in 84 patients
with clinically and biochemically characterized SLOS
(detection rate 96%), the mutational spectrum in the
DHCR7 gene. Forty different SLOSmutations, some fre-
quent, were identified. On the basis of mutation type
and expression studies in the HEK293-derived cell line
tsA-201, we grouped mutations into four classes: non-
sense and splice-site mutations resulting in putative null
alleles, missense mutations in the transmembrane do-
mains (TM), mutations in the 4th cytoplasmic loop (4L),
and mutations in the C-terminal ER domain (CT). All
but one of the tested missense mutations reduced protein
stability. Concentrations of the cholesterol precursor 7-
dehydrocholesterol and clinical severity scores correlated
with mutation classes. The mildest clinical phenotypes
were associated with TM and CT mutations, and the
most severe types were associated with 0 and 4L mu-
tations. Most homozygotes for null alleles had severe
SLOS; one patient had a moderate phenotype. Homo-
zygosity for 0 mutations in DHCR7 appears compatible
with life, suggesting that cholesterol may be synthesized
in the absence of this enzyme or that exogenous sources
of cholesterol can be used.
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Introduction
Smith-Lemli-Opitz syndrome (SLOS [MIM 270400])
(Smith et al. 1964) is an autosomal recessive metabolic
disorder that causes variable congenital anomalies, in-
cluding microcephaly, cleft palate, syndactyly of toes 2/
3, polydactyly, visceral malformations, variable struc-
tural anomalies of the heart, ambiguous genitalia in
males, failure to thrive, and mental retardation. SLOS
is a relatively common disorder, with an estimated in-
cidence of ∼1/20,000 live births in individuals of Eu-
ropean ancestry, but it has an apparently lower incidence
in most other ethnic groups (Opitz 1994; Cunniff et al.
1997; Kelley 1997). Patients typically show reduced lev-
els of cholesterol and increased levels of 7-dehydrocho-
lesterol (7DHC) and 8-dehydrocholesterol (8DHC) in
plasma and tissues (Irons et al. 1993; Kelley 1995),
which are caused by an apparent defect in the final step
of cholesterol biosynthesis. This step is catalyzed by the
enzyme D7-sterol reductase (DHCR7) (Tint et al. 1994),
which is localized in the membrane of the endoplasmic
reticulum (ER). SLOS is the best-studied example of ge-
netically determined disorders of postsqualene choles-
terol synthesis. Defects in an enzyme located upstream
(D8–D9-sterol isomerase) cause X-linked Conradi
Hu¨nermann–type chondrodysplasia punctata (MIM
302960) (Braverman et al. 1999; Derry et al. 1999; Kel-
ley et al. 1999). Before the discovery of the biochemical
defect, two clinical forms of SLOS—known as “mild”
(type I) and “severe” (type II)—had been distinguished
clinically (Curry et al. 1987). However, the finding that
both forms are associated with qualitatively the same
abnormality of sterol metabolism indicated that the two
forms represent two extremes of a single disorder (Cun-
niff et al. 1997).
We have recently cloned the cDNA for human
DHCR7 (E.C.1.3.1.21), which catalyzes the conversion
of 7DHC to cholesterol (Moebius et al. 1998), and have
demonstrated that mutations in the gene cause SLOS
(Fitzky et al. 1998). Mutations in DHCR7 in patients
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who have SLOS were also found by Wassif et al. (1998)
and by Waterham et al. (1998). The gene, which was
assigned to chromosome 11q13, contains nine exons and
eight introns and spans ∼14 kb (Fitzky et al. 1998). The
first two exons are noncoding, whereas the start codon
is localized in exon 3. The cDNA spans 2,646 bp and
encodes a 475-amino-acid open reading frame (Moebius
et al. 1998).
In the present study, PCR conditions were established
to amplify all exons and exon-flanking intron regions of
the DHCR7 gene. SSCP, denaturing gradient-gel elec-
trophoresis (DGGE), and automated sequencing of the
PCR products were used to screen for mutations of
DHCR7 in 84 patients with biochemically confirmed
SLOS, thereby permitting the investigation of pheno-
type-genotype correlation in SLOS.
Patients and Methods
Patients
The study population included 84 unrelated patients
with SLOS who are from the United States, Germany,
and the United Kingdom (table 1). All but one patient
(D61, who had mostly American Cherokee heritage)
were white. Of these 84 patients, 13 had been includ-
ed in a previous analysis (Fitzky et al. 1998). In 62 pa-
tients, the diagnosis was established by quantification of
7DHC, by use of gas chromatography/mass spectrom-
etry (Kelley 1995). When adequate clinical information
was available, patients ( ) were further character-n = 55
ized by a scoring system, wherein malformations in each
of 10 embryologically distinct areas were scored as either
“1” or “2” and the sum normalized to 100 (Kratz and
Kelley 1999). When patients whose SLOS was scored in
this manner were adjudged qualitatively, by clinical ge-
neticists, as having mild, moderate, or severe forms, the
mean severity scores were 10, 39, and 72, respectively.
Mutation Analysis
Amplification.—High-molecular-weight DNA sam-
ples from the probands were isolated from either pe-
ripheral blood leukocytes or fibroblasts, by use of es-
tablished procedures. Exons 1–9 and their flanking
sequences were amplified by use of PCR (Saiki et al.
1985). The amplification primers for exons 3–9 were
described elsewhere (Fitzky et al. 1998). In the present
analysis, the 3′ and 5′ parts of the coding sequence of
exon 9 were amplified separately. The primers used for
exons 1 and 2 were as follows: 1 forward, gtccggccgctg-
ccgaatggc; 1 reverse, cactgcgcacaccttcccctg; 2 forward,
ggccttgagcgtctgccctctcc; and 2 reverse, catagcctgcgccca-
cgatccagg. The amplification was done over 35 cycles,
with each cycle consisting of denaturation for 45 s at
95C ; annealing for 45 s at 55C (for exon 7), 57C
(for exons 1–3, 5, 6, and 8), and 62C (for exons 4 and
9); and extension for 45 s at 72C. The reaction mixture
contained 50–100 ng DNA; 200 ng each primer; 200
mM each of dGTP, dCTP, and dATP; 800 mM dUTP; 3.5
mM MgCl2; 10 mM Tris-HCl pH 8.8; and 1 U Taq
polymerase (Dynazyme II; Finnzymes).
SSCP.—Exons 1–8 and the 5′ and 3′ ends of exon 9
were screened for mutations, by use of SSCP. A total of
7 ml PCR product was subjected to electrophoresis done
on a mutation-detection–enhancement (MDE; FMCBio-
products) gel and was then silver-stained as described
elsewhere (Budowle et al. 1991).
DGGE.—For DGGE analysis of exons 4 and 9 (3′
end), 30-bp-long CG clamps were included at the 5′ end
of the forward primer (exon 4) and at the 3′ end of the
reverse primer (exon 9), respectively (Sheffield et al.
1989). The melting profiles of the fragments were an-
alyzed by use of the computer algorithm Melt 87 (Ler-
man and Silverstein 1987). Gels were stained with eth-
idium bromide.
Sequencing.—The amplified DNA was subjected to
electrophoresis on agarose gels from which the frag-
ments were excised, were purified with QIA Quick PCR
Purification Kit (Quiagen), and were sequenced, on the
ABI Genetic Analyzer 310, with the Big Dye Termina-
tor Cycle Sequencing Ready Reaction Kit (PE Bio-
systems).
In vitro mutagenesis, heterologous expression,
and quantitative analysis of overexpressed pro-
tein.—Most of the identified point mutations were in-
troduced, by in vitro mutagenesis, into the cDNA of
human DHCR7 fused with an N-terminal c-myc ep-
itope, as described elsewhere (Fitzky et al. 1998).
Wild-type and mutated cDNAs were subcloned into
pCIneo (Promega) with XhoI-NotI restriction sites
and were heterologously expressed in the HEK293-
derived cell line tsA-201. For quantitative analysis of
DHCR7 protein expression, 40 mg microsomal protein
were separated on 12% (wt/vol) SDS-polyacrylamide
gels, were transferred to polyvinyldifluoride mem-
branes, and were immunostained, against the c-myc
epitope, with 50 ng antibody 9E10 per ml (Oncogene
Science). 9E10 c-myc immunoreactivity was visualized
with the use of 35 mCi purified [125J]-labeled anti-
mouse immunoglobulin G (NEN) per ml and was
quantified by membrane slicing and g-counting
(Fitzky et al. 1998). The data shown in table 2 are
the results from three independent transfections.
Statistics
All patients were included in the genotype-phenotype
analysis. To include patients whose exact severity scores
were unknown but whose phenotype descriptions were
available ( ), we assigned the scores “10, ” for then = 14
Table 1
Severity Scores, Age at Diagnosis, and Plasma Sterol Concentrations of Patients with SLOS
Patient (ID Number) Severity Score
Age at Diagnosis
(years)
Cholesterol
(mg/ml)
8DHC
(mg/ml)
7DHC
(mg/ml)
Those with complete data set:
1 (SLO1) 25 1.6 ND 45.7 156
2 (SLO3) 5 .6 1,160 69 117
3 (SLO7) 29 ND 342 94 107
4 (SLO8) 20 1.0 950 72 89
5 (SLO10) 25 .7 ND 85.6 162
6 (SLO11) 26 .11 ND 82 112
7 (SLO13) 10 .25 550 21 127
8 (SLO14) Severe .04 ND ND ND
9 (25644) Severe .015 162 169 173
10 (25719) Severe Fetus NDa NDa NDa
11 (D61) 17 3.4 1,059 26 26
12 (D64) 22 .01 145 45 52
13 (D65) 17 .5 543 95 177
14 (D66) 31 7.0 542 76 73
15 (D67) 12 27.0 833 84 110
16 (D68) 22 .1 310 73 88
17 (D69) 40 Fetus ND ND ND
18 (D70) Mild Adult 1,190 ND 14
19 (D72) 69 .01 231 ND 218
20 (D73) 56 4.4 280 131 254
21 (D75) 19 .6 119 108 73
22 (D76) 39 .5 351 ND 470
23 (D78) 12 .03 1,000 58 41
24 (D79) 56 .01 ND ND ND
25 (D80) 100 Fetus 23.3 2.2 9.3
26 (D81) 28 1.42 42 68 148
27 (D82) 56 ND ND ND 6.9
28 (D85) 36 .25 236 109 231
29 (D86) 6 13.0 1,151 44 46
30 (D87) 75 Fetus ND ND ND
31 (D89) 72 Amnion 18.9 ND 13.8
32 (D90) 50 .02 228 118 200
33 (D91) 17 7.0 510 62 59
34 (D92) 6 3.0 1,142 23 12
35 (D95) 39 .04 88 72 112
36 (D97) 6 .02 563 82 84
37 (D99) Mild 35.0 1,272 259 134
38 (D100) 39 27.0 599 60 70
39 (D104) Moderate 8.0 164 260 288
40 (D105) 75 .02 153 ND 138
41 (D106) Severe ND 170 ND 201
42 (D107) 56 .15 236 180 156
43 (D108) Severe Fetus ND ND ND
44 (D111) 33 6.2 340 107 292
45 (D112) 33 21.0 500 101 221
46 (D113) Severe .17 98 72 96
47 (D114) Moderate 10.0 373 108 108
48 (D115) 44 1.39 139 170 313
49 (D116) 22 8.0 748 68 70
50 (D117) 55 1.3 275 50 105
51 (D118) Mild 10.0 1,149 23 14
52 (D119) 17 .1 326 17 19
53 (D120) 22 .73 315 46 140
54 (D121) 50 .04 40 46 29
55 (D123) 33 .01 170 160 170
56 (D124) 25 .03 41 43 104
(continued)
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Table 1 Continued
Patient (ID Number) Severity Score
Age at Diagnosis
(years)
Cholesterol
(mg/ml)
8DHC
(mg/ml)
7DHC
(mg/ml)
57 (D125) 11 41.0 1,207 122 291
58 (D127) 33 26.58 912 169 371
59 (D128) 39 .83 69 92 217
60 (D129) 13 5.00 1,385 61 84
61 (D130) 38 .91 621 73 143
62 (D138) 31 .01 410 75 85
63 (D139) 6 5.75 1,377 10 8
64 (D141) Moderate 3.8 432 94 111
65 (D142) Severe Fetus ND ND ND
66 (D144) 38 16.33 410 46 60
67 (D145) 6 3.8 1,738 18 18
68 (D152) Moderate 10.75 1,358 29 62
69 (D163) 175 Fetus 30b 5 20
Those for whom no severity score was available:
70 (SLO2) ND 2.5 910 ND 432
71 (SLO4) ND ND 1,550 ND 100
72 (SLO5) NDc .06 340 ND 67
73 (SLO6) ND 1 1,152 77.5 100
74 (SLO9) ND .5 700 ND 89
75 (SLO12) NDc .08 340 140 357
76 (1980) ND ND ND ND ND
77 (8a) ND ND ND ND ND
78 (860) ND ND 280 ND 438
79 (13141) ND 7 3.51 420 378
80 (23212) ND .02 81 317 469
81 (25718) NDc .104 313 84.6 157
82 (D84) ND 5.0 906 37 39
83 (D122) ND ND 645 92 220
84 (D135) ND ND ND ND ND
NOTE.—ND = not determined.
a Elevated 8DHC in amniotic fluid and fetal tissue.
b Amniotic fluid.
c Most likely severe, because of very early death.
mild phenotype; “39, ” for the moderate (classic) phe-
notype; and “72,” for the severe phenotype, as noted
earlier. The Kruskal-Wallis, Mann-Whitney, and x2
goodness-of-fit tests were applied as indicated. Spearman
correlation coefficients (RS) and linear regression were
calculated by use of the software package SPSS for Win-
dows (release 8.0.0. 1997; SPSS). Analysis of variance
(ANOVA) was used to compare the variance of quan-
titative biochemical variables both within and between
genotypes.
Results
Mutational Spectrum
All of the exons encoding the open reading frame, as
well as the untranslated exons 1 and 2, were screened
by means of either SSCP (exons 1–9 [5′ end] and 9 [3′
end]) or DGGE (exons 4 and 9 [3′ end]) performed in
the 84 patients. Exons showing shifted or ambiguous
banding patterns were sequenced. However, in those pa-
tients for whom either no mutation or only onemutation
was found by use of this strategy, all exons were se-
quenced. This resulted in a mutational detection rate of
96%. In all patients with biochemically confirmed SLOS,
we found 1 mutation. For only six patients were we
unable to identify a 2d mutation. Three mutations were
found in two of the patients (D80 and D111). This was
confirmed by analysis of the parents. The genotypes of
these patients were IVS 8–1GrC; R 352Q/R352Q (D80)
and IVS 8-1GrC; T93 M/IVS 8-1GrC (D111).
We identified a total of 40 different mutations, several
of which were recurrent, in the patients. In addition,
several polymorphic silent mutations, some of which
have previously been described elsewhere (Fitzky et al.
1998), were found. Newly identified sequence variants
causing no amino acid change were 285ArG, 969GrT,
1350CrG, and 223TrC. Mutation 223TrC oc-
curred in 2/40 healthy control individuals.
Table 2 lists all identified SLOS mutations. The ma-
jority (36/40 [90%]) were missense mutations. The
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Table 2
Spectrum of SLOS-Causing Mutations in the DHCR7 Gene
Mutation Class and
Nucleotide Change Exon
Effect on
Coding
Sequence
Conserved
Amino Acid
Localization
in the Protein
Expression
(%)
Wild type:
None 100
0:
IVS8-1GrC 9 Frameshift
(385–412 and IVS51-5)del 5 Frameshift
720–735 del 6 Frameshift
453GrA 6 W151X No 0
TM:
151CrT 4 P51S Yes TM
278CrT 4 T93M Yes TM !5
296TrC 4 L99P Yes TM !5
321GrC 4 Q107H Yes TM
326TrC 5 L109P Yes TM
440GrA 6 G147D Yes TM
461CrT 6 T154M Yes TM !5
470TrC 6 L157P No TM
506GrC 6 S169L No TM
549GrC 6 W182C Yes TM !5
724CrT 7 R242C Yes TM !3
740CrT 7 A247V Yes TM 5
841GrA 8 V281M Yes TM
866CrT 8 T289I Yes TM
931TrG 8 C311G Yes TM
932GrA 8 C311Y Yes TM
970TrC 9 Y324H Yes TM
976CrT 9 V326L Yes TM !10
1055GrA 9 R352Q Yes TM
1054CrT 9 R352W Yes TM !3
1058TrC 9 V353A Yes TM
1222TrC 9 Y408H Yes 4th Cytoplasmic loop/TM
1228GrA 9 G410S Yes 4th Cytoplasmic loop/TM 4
1228GrC 9 G410R Yes 4th Cytoplasmic loop/TM
4L:
1084CrT 9 R362C Yes 4th Cytoplasmic loop
1139GrA 9 C380Y No 4th Cytoplasmic loop 40
1138TrC 9 C380R No 4th Cytoplasmic loop 5
1138TrA 9 C380S No 4th Cytoplasmic loop
1190CrT 9 S397L Yes 4th Cytoplasmic loop
1210CrT 9 R404C Yes 4th Cytoplasmic loop 2
1210CrA 9 R404S Yes 4th Cytoplasmic loop
CT:
1327CrT 9 R443C Yes C-terminus !3
1337GrA 9 R446Q Yes C-terminus
1342GrC 9 E448Q Yes C-terminus
1342GrA 9 E448K Yes C-terminus 5
1349GrT 9 R450L Yes C-terminus 90
four nonmissense mutations included one out-of-
frame 15-bp deletion (720–735 del), a 33-bp deletion
comprising 5 bp of a splice-donor site (385–412del
and IVS 51–5del), one splice-site mutation (IVS8-
1GrC) resulting in a 134-bp insertion because of alter-
native splicing, and a nonsense mutation (W151X); all
of these nonmissense mutations are predicted to result
in truncated proteins and may also cause mRNA insta-
bility (Maquat 1996). Mutations occurred in the trans-
lated exons 4–9 but were clustered in exon 9, in which
∼50% (21/40) of the mutations were found. Several co-
dons had two or three different mutations (e.g., C380S,
C380R, and C380Y) (fig. 1).
The highest allele frequency was observed for the
splice-site mutation IVS8-1GrC, which was found 48
times among the 168 SLOS alleles ( of all SLOSP = .29
alleles). Four homozygotes for this mutation were found,
which is close to the expected number (table 3). The
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Figure 1 Distribution of SLOS-causingmutations in theDHCR7
gene. Exons are drawn to scale; introns are not drawn to scale. The
ATG initiation codon is indicated. The hatched boxes with roman
numerals denote the transmembrane domains. The cytosolic loop in
exon 9 (cytosol) and the C-terminus, assumed to be located in the
lumen of the ER, are indicated.
Table 3
Frequent Mutations in the DHCR7 Gene of 84 Patients with SLOS
MUTATIONa EXON
NO. OF
ALLELES
( )n = 168
FREQUENCY
(P)
NO. OF
HOMOZYGOTES
Identified Expected
IVS8-1GrC 9 49 .29 4 7.0
R404C 9 18 .11 5 1.0
T93M 4 14 .08 ) .6
W151X 6 14 .08 1 .6
V326L 9 12 .07 ) .43
R352W 9 5 .03 ) .11
S169L 6 4 .02 ) .03
E448K 9 3 .02 ) .03
R242C 7 3 .02 ) .03
Y324H 9 3 .02 ) .03
R352Q 9 3 .02 1 .03
P51S 4 2 .01 ) .01
L99P 4 2 .01 ) .01
T154M 6 2 .01 ) .01
T289I 8 2 .01 ) .01
C380Y 9 2 .01 1 .01
R404S 9 2 .01 ) .01
G410S 9 2 .01 ) .01
R446Q 9 2 .01 ) .01
a All mutations other than those listed were represented by a single
chromosome.
missense mutation R404C also occurred with a fre-
quency of SLOS alleles that was 1.1, and mutations
T93M, W151X, and V326L had frequencies 1.05. It
is notable that two of the truncating mutations
(IVS8–1GrC and W151X) were among the five most
frequent SLOS mutations identified, accounting for one-
third of all SLOS mutations.
Homozygotes were also identified for R404C,
W151X, R352Q, and C380Y. None was from a known
consanguineous marriage. However, for one of the mu-
tations (R404C), significantly more homozygotes (n =
) were identified than were expected ( ). Three of5 n = 1
the five R404C homozygotes were from the same Lou-
isiana parish and have in common an ancestor of French
origin dating back to the early 18th century. Hence, this
mutation most likely represents a French founder muta-
tion.
Of the 36 missense mutations, 31 affected conserved
residues (i.e., residues identical in the human, mouse,
and plant DHCR7 genes [Fitzky et al. 1998]). Only five
mutations changed a nonconserved residue. Three of
these changed the same Cys residue (C380 to Y, R, and
S, respectively), and one introduced a proline into a pre-
sumably a-helical hydrophobic transmembrane domain
(L157P). All of these mutations, by virtue of the type of
amino acid change introduced, are likely to be SLOS-
causing mutations.
The parents of patients D75, SLO14, and 25720, who,
according to the results of SSCP/sequencing, appeared
to be homozygotes, were analyzed, to establish that they
were true homozygotes and that they were not, for ex-
ample, carrying a deletion for one allele. In all cases,
both parents were heterozygous for the respective mu-
tation. Together with the high mutation-detection rate
(96%), this result suggests that no frequent large dele-
tions or other SLOS-causing mutations exist and that
patients identified as homozygotes are true homozy-
gotes.
Localization of Missense Mutations in the Protein and
Classification of Mutations
The DHCR7 protein is localized in the membrane of
the ER and has nine putative transmembrane domains
and one large cytoplasmic loop (the 4th cytoplasmic
loop) (Fitzky et al. 1998; Moebius et al. 1998). The C-
terminus is predicted to be located in the lumen of the
ER. The 36 missense mutations have a characteristic
distribution along this topography (fig. 1). Twenty-one
mutations are located in the transmembrane domains,
three are at the border of transmembrane domains 8 and
408 Am. J. Hum. Genet. 66:402–412, 2000
Figure 2 A, Correlation between severity score and DHC frac-
tion. RS and linear regression coefficients are shown. B, Box-plot di-
agram illustrating the distribution of DHC fraction values within gen-
otypes. C, Box-plot diagram illustrating the distribution of severity
scores within genotypes. Black lines within boxes in B and C represent
medians. Boxes represent the range, accommodating 95% of values,
and vertical lines represent the total range for the group.
9, seven are in the 4th cytoplasmic loop, and five are
located in the C-terminus of the protein. Hence, there
is clustering of the missense mutations in the transmem-
brane domains. These mutations are likely to affect pro-
tein stability, which has already been demonstrated for
some of the mutations (Fitzky et al. 1998). Notably, all
but one (R450L) of the missense mutations analyzed in
the present study also reduced protein expression (table
2). At least some of the mutations in the C-terminal ER
domain of DHCR7, including R450L, also reduce the
enzymatic activity (B. U. Fitzky, unpublished data). On
the basis of the localization of the amino-acid sequence
changes in the protein and their presumed functional
consequences, we categorized SLOS mutations into four
classes (table 2): truncating mutations predicted to result
in functional null alleles (0 mutations); mutations lo-
cated in or close to the transmembrane domain (TM
mutations); mutations in the 4th cytoplasmic loop (4L
mutations); and mutations affecting the C-terminal do-
main (CT mutations).
Genotype-Phenotype Correlation
The classification of mutations into four distinct types
(O, TM, 4L, and CT mutations) was used to analyze
whether a relation exists between DHCR7 genotypes
and SLOS phenotypes. Of the 10 possible genotype com-
binations, 7 (0/0 = 7, TM/TM = 6, 4L/4L = 6, 0/TM =
40, 0/4L = 10, TM/4L = 2, and TM/CT = 7) were rep-
resented in the sample.
Genotypes were related to the biochemical pheno-
types, by comparison of various sterol metabolite con-
centrations and their ratios with the clinical phenotypes
and by application of the described scoring system.
When total cholesterol, 7DHC, 8DHC, the 7DHC/cho-
lesterol ratio, and the sum of 7DHC plus 8DHC ex-
pressed as a fraction of total sterols (DHC fraction) were
compared both within and between genotypic classes,
they were more similar within genotypes than between
genotypes (ANOVA, ). We first analyzed the re-P = .001
lation between the patients’ sterol parameters and their
severity scores, and we found a significant correlation
between the DHC fraction and the severity score (fig.
2A). There was also a clear correlation between theDHC
fraction and the genotypes ( , ) (fig.R = 0.548 P ! .001s
2B). Patients with two TM mutations or with one TM
and one CT mutation had the lowest DHC fraction, on
average, whereas those with two 4L mutations, those
whowere homozygotes and compounds for 0mutations,
and those with one 0 and one 4L mutation had the
highest DHC fractions. Patients with 0/TM and 4/TM
mutations had intermediate values. Despite the substan-
tial differences among the various means, there was
broad overlap between the groups. The correlation of
genotypes with the sterol levels suggested that the geno-
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Table 4
Distribution of DHCR7 Genotype Classes, in Relation to Age at Diagnosis and
Severity, in Patients with SLOS
CHARACTERISTIC
GENOTYPE CLASS
TM/TM TM/CT 0/TM 4L/TM 0/4L 4L/4L 0/0
Age (years):
1 4 2 16 2 6 4 6
11 2 4 19 0 4 1 1
Disease severity:
Milda 2 3 12 1 2 1 0
Moderateb 2 1 13 1 5 2 1
Severec 0 1 5 0 2 2 6
a Severity score !25.
b Severity score 25–50.
c Severity score 150.
types might also correlate with the severity scores. In-
deed, average disease severity increased in almost the
same order with genotypes as did genotypes with the
DHC fraction. Patients in the TM/TM and TM/CT
groups were, on average, less severely affected than were
patients with two 0 mutations or those with two mu-
tations in the 4th cytoplasmic domain (fig. 2C). For this
correlation, the coefficient was ( ).R = .370 P ! .006s
Thus, in summary, we found, among our patients with
SLOS, a strong correlation of both the genotypes and
the cholesterol metabolites with their clinical severity.
We further evaluated the genotype distribution among
patients in the three classes of severity: severe (score
150), moderate (score 125 and !50), and mild (score
!25). Genotypes 0/0 and 4L/4L were significantly more
frequent in patients with a severe phenotype, whereas
genotypes TM/CT and TM/TM occurred predominantly
in patients with a mild/moderate phenotype. This dif-
ference was significant ( ).P = .001
Correlation of Genotypes with Age at Diagnosis
We compared the age at diagnosis of term-delivered
patients for the three groups of severity. The group
with the lowest severity score (!25) had a significantly
higher age at diagnosis (mean age = 8.6 years 12.4;
), whereas the group with the highest severityn = 20
score (150) included the youngest patients (mean .29
years  .50; ). The difference in age at diag-n = 10
nosis between groups was significant (Kruskal-Wallis
test ). Because age at diagnosis correlates withP = .050
clinical severity, it should also correlate with geno-
type. The genotype distributions were therefore com-
pared between patients in whom SLOS was diagnosed
either at age !1 year ( ) or later in life (n = 37 n =1 2
), by means of the Mann-Whitney test, and they29
were found to be significantly different (table 4).
SLOS Phenotypes in Homozygotes or Compounds
for Presumed Functional Null Alleles of D7-Sterol
Reductase and Mutations in the Most Severe Cases
As shown in the genotype-phenotype correlation stud-
ies, patients with two functional null DHCR7 alleles
have the most severe phenotypes. Of the four patients
homozygous for the IVS8-1GrC mutation, three were
severely affected and were detected by prenatal ultra-
sound. These pregnancies were terminated. The other
IVS8-1GrC homozygote was moderately affected. The
only patient homozygous for the W151X stop mutation
also had a severe phenotype detected prenatally. The
compound heterozygote for W151X and IVS8-1GrC
had a severe phenotype (severity score 56) and died at
age 2 d.
In all, we studied 16 cases with a severity score 150
(table 5). The frequency of 0 alleles (.59) and of null
and 4L alleles combined (.78) was significantly higher
than that in the mild/moderate group ( ), and aP = .05
significant number of patients (10/16) were 0 and/or 4L
homozygotes or compounds. Only one had neither a 0
mutation nor a class 4L mutation.
Discussion
We analyzed the genotypes of a large cohort of pa-
tients with biochemically and clinically characterized
SLOS. This allowed us to address how the genotype
determines the biochemical and clinical phenotype. Two
groups of patients are from England and Germany, re-
spectively, but the majority of the patients are Americans
of European descent. Our sample therefore represents
major European populations. The large number of pa-
tients analyzed makes it likely that our study coversmost
of the existing spectrum of frequent mutations in the
DHCR7 gene.
In 168 alleles, we found a total of 40 different mu-
tations, of which 36 were missense mutations. The ma-
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Table 5
Mutations in the DHCR7 Gene in Patients with SLOS Who Have a Severity Score 150
Patient
Severity
Score Genotype
Mutation
Class Remarks
SLO14 Severe IVS8-1GrC/IVS8-1GrC 0/0 Died at age 22 d
D79 56 IVS8-1GrC/W151X 0/0 Died at age 2 d
D89 72 W151X/W151X 0/0 Termination
D108 Severe IVS8-1GrC/IVS8-1GrC 0/0 Termination
D163 175 IVS8-1GrC/IVS8-1GrC 0/0 Termination
25719 Severe IVS8-1GrC/IVS8-1GrC 0/0 Termination
D72 69 R404C/R404C 4L/4L Died at age 6 wk
D107 56 R404C/R404C 4L/4L Diagnosed at age .15 years, died at age 1 year
D105 75 W151X/S397L 0/4L Diagnosed at age .02 years, died during first weeks of life
25644 Severe IVS8-1GrC/ R404C 0/4L Baby, severe SLOS
D73 56 IVS8-1GrC/L109P 0/TM Diagnosed at age 4.4 years
D142 Severe IVS8-1GrC/T93M 0/TM Termination
D80 100 IVS8-1GrC/R352Q 0/TM Termination
D87 75 IVS8-1GrC/V326L 0/TM Termination
D113 Severe W151X/R352Q 0/TM Diagnosed at age .17 years
D117 55 V281M/R446Q TM/CT Diagnosed at age 1.3 years
jority of mutations was found in exons 9 (111), 6 (24),
and 4 (19), so that analysis of these three exons will
identify 190% of the mutations. Of the 40 mutations,
only 4 truncate the protein and remove essential func-
tional domains. These four mutations (W151X, IVS8-
1GrC, 385-412delIVS51-5del, and 720-735del)
presumably result in functional DHCR7 null alleles. In
fact, on western blotting, no protein was present in HEK
cells transfected with the W151X cDNA (table 2), and
there also was no enzyme activity present (B. U. Fitzky,
unpublished data).
Given that only a few null alleles exist, it is surprising
that two of them (IVS8-1GrC and W151X) accounted
for more than one-third of all mutations. Why are 0
mutations that frequent? To explain this conundrum, we
have to consider two possibilities. The two 0 mutations
(IVS8-1GrC andW151X) could confer a significant het-
erozygote advantage. If the 0 mutations are indeed se-
lected, it remains to be clarified why null alleles resulting
in 50% of wild-type activity in heterozygotes should be
preferred over hypomorphic alleles resulting in, for ex-
ample, 55% of biochemical activity in heterozygous car-
riers. In contrast, the high frequency of 0 mutations
could simply reflect the expansion of ancient populations
carrying these mutations. This view is supported by the
finding that two alleles carrying two different SLOS-
causing mutations were identified, both of which in-
volved the frequent IVS8-1GrC mutation. Hence, this
mutation seems to be old. Approximately another one-
third of the SLOS chromosomes contain four frequent
missense mutations (R404C, T93M, V326L, and
R352W) in the DHCR7 gene. Even so, it seems con-
ceivable that one or two mutations (e.g., IVS8-1GrC)
were preexistent in an expanding population. It is in-
triguing that the six mutations that account for two-
thirds of all DHCR7 alleles should have existed in the
people that populated Europe. SLOS is virtually absent
in Africans and Asians. Haplotype analysis has to be
applied to establish the history and spatial distribution
of frequent DHCR7 mutations and to discern both foun-
der effects from recurrent mutations and possible het-
erozygote advantage. In the absence of the six most fre-
quent mutations, the SLOS would be a rare disorder in
Europeans.
Most of the missense mutations target residues that
are conserved between plants and vertebrate enzymes,
suggesting that, in the protein, these sites are critical for
function (table 2). Of 30 mutated amino acid residues,
6 are hit two or even three times (table 2), underscoring
their potential importance for catalysis or protein fold-
ing. Two-thirds of the missense mutations were localized
either within or adjacent to the proposed nine trans-
membrane segments (table 2 and table 3). Such cluster-
ing in transmembrane domains is known from disease-
causing mutations in other genes (e.g., PMP22) (Nelis
et al. 1999). Whereas no mutations were found in the
N-terminus, several mutations were localized in the C-
terminus. One-fourth of the mutations targeted the 4th
cytoplasmic loop between transmembrane segments 8
and 9. This region was suggested to bind NADPH, the
indispensable cofactor of 7DHC reduction (Fitzky et al.
1999). Even though a putative sterol-binding site was
identified in TMS5-8 (Bae et al. 1999), no functional
domains of the enzyme have been confirmed experi-
mentally. Therefore, in the present study, we have ar-
bitrarily classified the missense mutations, according to
their topological localization in the transmembrane re-
gion (TM), the 4th cytoplasmic loop (4L), and the C-
terminus (CT). Functional analysis, by expression of
DHCR7 mutations in mammalian cells, demonstrated
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that all but one of the missense mutations result in un-
stable protein (table 2). The only mutation that has nor-
mal protein expression (R450L) was present in patient
D139, who has one TM mutation and one CT mutation
(genotype R242C, R450L). This is particularly interest-
ing, because this mildly affected patient has biochemical
characteristics that differ significantly from those of
other patients with SLOS (Anderson et al. 1998). Further
biochemical studies are needed to characterize this and
other CT mutations in detail.
A characteristic feature of SLOS is the phenotypic var-
iability of a few severely affected patients ( in thisn = 16
study) and a larger number of patients with a mild or
moderate clinical phenotype ( in this study). Wen = 49
sought to address whether the clinical and biochemical
phenotypes are associated with certain genotypes and
found a strong correlation between clinical and bio-
chemical phenotype and both the type and localization
of mutations. Mild phenotypes were more frequent
among patients with two missense mutations in either
the transmembrane segments or the C-terminus (TM/
TM, TM/CT), whereas severe phenotypes were more
abundant among patients who are homozygous or com-
pounds for 0 mutations or missense mutations in the
4th cytoplasmic loop (0/0, 0/4L, and 4L/4L). Therefore,
not only null alleles but, also, mutations in the 4th cy-
toplasmic loop of the enzyme are a major determinant
of phenotypic severity. It would be highly desirable to
identify the function of this domain.
Although our study unequivocally established that the
clinical and biochemical phenotypes correlate with the
genotype, we cannot predict the phenotype from the
genotype, and vice versa, probably because the corre-
lation is obscured by two factors: first, additional en-
vironmental or genetic determinants that remain to be
identified can modify the phenotype; second, our clas-
sification of mutations does not reflect the unknown bi-
ochemical consequences of all mutations within a given
class in vivo. Identification of those frequent patients
who have a 0 mutation combined with a missense mu-
tation (0/TM, 0/4L) paves the way for analysis of the
functional consequences of missense mutations in vivo,
to further refine our classification of mutations. A side-
by-side comparison of environmental factors, metabolic
characteristics, and genetic markers in patients with
identical genotypes might identify the postulated mod-
ifiers of the phenotype. Consideration of the genotype
may also be important in studies that measure the re-
sponse of patients to cholesterol feeding, which report-
edly has beneficial effects on the behavioral phenotype
of patients with SLOS (Irons et al. 1994; Nwokoro and
Mulvihill 1997; Cunniff et al. 1997; Angle et al. 1998).
The response of patients to dietary cholesterol may also
depend on genotype.
An indispensable step in the biosynthesis of choles-
terol from the intermediate lanosterol is the reduction
of the D7-bond of 7DHC. In the absence of the enzyme
D7-sterol reductase because of two DHCR7 null alleles,
the reduction of 7DHC should be abolished. A funda-
mental biological question is whether vertebrates can
develop without endogenous cholesterol biosynthesis.
Patients with two 0 mutations might be a genetic model
for a complete block in cholesterol synthesis. Seven pa-
tients with two 0 mutations indeed had a severe phe-
notype that led to termination of the pregnancy in four
patients and early postnatal death in three (table 5).
However, one patient had a moderate phenotype despite
two 0 mutations (IVS8-1GrC homozygote), implying
that other, yet-to-be identified determinants of the phe-
notype may exist. There are at least four possibilities to
explain the presence of cholesterol and a moderate phe-
notype in living patients with SLOS with two 0 muta-
tions: (i) there might be another source of DHCR7 ac-
tivity, (ii) there could be another pathway of cholesterol
synthesis not requiring DHCR7, (iii) the IVS8-1GrC
splice mutation may be leaky, allowing for the presence
of some normal mRNA, and (iv) there may be exogenous
sources of cholesterol (e.g., transport of lipoproteins
through the placenta).
The detailed mechanism(s) by which mutations in the
DHCR7 affect cholesterol metabolism and result in the
SLOS phenotype still need to be clarified. Ultimately, this
will help in the understanding of how cholesterol and
the intermediates of sterol metabolism determine mor-
phogenesis and brain function.
Note added in proof.—After submission of the man-
uscript, seven DHCR7 mutations were detected in 12
additional patients with SLOS (R. Berberich and H. J.
Menzel, personal communication).
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